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550Objectives: Recent studies suggest adverse events associated with aprotinin in adults may not occur in children,
and there is interest in further pediatric studyof aprotinin.However, there are limited contemporary data comparing
aprotinin with other available antifibrinolytics (aminocaproic acid [ACA] and tranexamic acid [TXA]) to guide
current practice and aid in potential trial design.Weperformed a comparative analysis in a largemulticenter cohort.
Methods: The Society of Thoracic Surgeons Congenital Heart Surgery Database (2004-2008) was linked to
medication data from the Pediatric Health Information Systems Database. Efficacy and safety outcomes were
evaluated in multivariable analysis adjusting for patient and center factors overall and in neonates and those un-
dergoing redo sternotomy.
Results: A total of 22,258 patients (25 centers) were included: median age, 7.6 months (interquartile range,
2.6-43.4 months). Aprotinin (vs no drug) was associated with a significant reduction in combined hospital mor-
tality/bleeding requiring surgical intervention overall (odds ratio [OR], 0.81; 95% confidence intervals [CI],
0.68-0.91) and in the redo sternotomy subgroup (OR, 0.57; 95%CI, 0.40-0.80). Therewas no benefit in neonates
and no difference in renal failure requiring dialysis in any group. In comparative analysis, there was no differ-
ence in outcome in aprotinin versus ACA recipients. TXA (vs aprotinin) was associated with significantly
reduced mortality/bleeding requiring surgical intervention overall (OR, 0.47; 95% CI, 0.30-0.74) and in neo-
nates (OR, 0.30; 95% CI, 0.15-0.58).
Conclusions: These observational data suggest aprotinin is associated with reduced bleeding and mortality in
children undergoing heart surgery with no increase in dialysis. Comparative analyses suggest similar efficacy of
ACA and improved outcomes associated with TXA. (J Thorac Cardiovasc Surg 2012;143:550-7)Aprotinin was the most commonly used antifibrinolytic
medication in children undergoing heart surgery until it
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The Journal of Thoracic and Cardiovascular Surgreporting increased mortality and renal failure.1,2 As
a result, aprotinin is also no longer available to children
undergoing heart surgery.3 Recent studies have suggested
that the adverse events associated with aprotinin in adults
may not occur in children. We4 previously evaluated safety
outcomes in more than 30,000 children undergoing heart
surgery and found that aprotinin was not associated with in-
creased mortality or dialysis. This previous study was lim-
ited by the use of administrative data, focused on safety
outcomes only, and did not compare aprotinin with other
antifibrinolytic medications (aminocaproic acid [ACA]
and tranexamic acid [TXA]). The few previous comparative
analyses evaluating these medications have been limited by
small sample size.5,6
Thus, although there is interest in further prospective
study of aprotinin in children, there are limited contempo-
rary data comparing aprotinin with other available antifibri-
nolytic medications to guide current practice and aid in
planning future prospective study. The purpose of the pres-
ent study was to evaluate the comparative outcomes associ-
ated with aprotinin, ACA, and TXA in a large multicenter
cohort. We first evaluated outcomes associated with aproti-
nin versus no drug before 2007 when aprotinin was most
widely used. We then subsequently assessed comparative
outcomes associated with aprotinin, ACA, and TXA duringery c March 2012
Abbreviations and Acronyms
ACA ¼ aminocaproic acid
CI ¼ confidence interval
EACTS ¼ European Association for
Cardiothoracic Surgery
ICD-9 ¼ International Classification of
Diseases, Ninth Revision
OR ¼ odds ratio
PHIS ¼ Pediatric Health Information Systems
STS-
CHS
¼ The Society of Thoracic Surgeons
Congenital Heart Surgery (Database)
TXA ¼ tranexamic acid
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D2007 to 2008 when use transitioned from aprotinin to the
other 2 medications. We evaluated the overall cohort of
children undergoing heart surgery, and the subgroups un-
dergoing redo sternotomy and neonates as these groups
may be more prone to bleeding.3,7METHODS
Data Source
De-identified data from the Pediatric Health Information Systems
(PHIS) Database and The Society of Thoracic Surgeons Congenital Heart
Surgery (STS-CHS) Database were used for this analysis. Data from 30
centers participating in both databases from 2004 to 2008were linked using
the method of ‘‘indirect identifiers’’ as previously described and verified.8
Overall, data on 90% of 45,830 eligible patients at these centers were suc-
cessfully linked using this methodology. Through linking these data, we are
able to capitalize on the strengths of both data sets and use the detailed di-
agnosis and procedure information in the STS-CHS Database and medica-
tion data from the PHIS Database, as described below.
The PHIS Database is a large administrative database containing in-
patient data from 41 pediatric hospitals in the United States affiliated
with the Child Health Corporation of America. The database currently con-
tains information from more than 4.6 million inpatient discharges. Data
quality and reliability are assured through a joint effort between Child
Health Corporation of America and participating hospitals. Data collected
include demographics, diagnoses, and procedures (using International
Classification of Diseases, Ninth Revision [ICD-9] coding), in-patient out-
comes data, and resource use data from the hospital bill including pharma-
ceuticals, imaging, laboratory studies, and hospital charges.
The STS-CHS Database is the largest clinical pediatric heart surgery
data registry in the world. It currently contains data on more than
160,000 operations performed since 1998. The STS-CHS Database con-
tains preoperative, operative, and outcomes data on all patients undergoing
pediatric heart surgery at participating centers. Diagnoses and procedures
are coded using the International Pediatric and Congenital Cardiac Code,
which was developed through an international collaborative effort of pedi-
atric cardiologists and congenital heart surgeons.9 Data quality and reliabil-
ity are assured through intrinsic verification of data as well as a formal
process of site visits and data audits.10
This study was approved by the institutional review boards at Duke
University Medical Center and The Children’s Hospital of Philadelphia
with waiver of informed consent. The study was also reviewed and ap-
proved by the STS-CHS Database Task Force and Child Health Corpora-
tion of America in compliance with their PHIS Database External Use
Guidelines.The Journal of Thoracic and CaStudy Population
Thirty centers (n ¼ 41,371 patients with successfully linked data as de-
scribed earlier) were eligible for inclusion. Centers with more than 15%
missing data for any STS-CHS study variable were excluded (n ¼ 5 cen-
ters); whereas the STS-CHS Database contains nearly complete data for
the required standard data fields regarding procedure and in-hospital mor-
tality, not all centers submit complete data for the other variables in the
STS-CHS Database, and it is therefore standard practice to exclude centers
with more than 15%missing data for key study variables to maximize data
integrity and minimize missing data). This left 25 centers (n ¼ 32,660 pa-
tients) eligible for inclusion. Patients with missing PHIS medication data
(n ¼ 1805) were excluded. STS-CHS data were used to identify patients
undergoing any surgery classified in The Society of Thoracic Surgeons–
European Association for Cardiothoracic Surgery (STS-EACTS) risk strat-
ification system (category 1 ¼ lowest mortality risk, category 5 ¼ highest
mortality risk).11 This system was recently developed on the basis of em-
piric data from nearly 80,000 patients. It includes a greater number of op-
erations compared with other risk stratification systems.11 Ninety-seven
percent of the remaining 30,855 eligible patients were classified in the
STS-EACTS system; only those patients undergoing surgery involving car-
diopulmonary bypass (n¼ 22,485) were included. Only the first cardiovas-
cular operation of the admission was analyzed, and patients who received
more than 1 of the drugs of interest on the day of the operation and those
with missing weight data were excluded. This left a cohort of 22,258 pa-
tients from 25 centers.
Data Collection
Data were collected from both the STS-CHS and PHIS databases (as
noted below for each variable). These included age (PHIS), prematurity
(PHIS, collected for neonates only using ICD-9 codes for gestational
age<37weeks), sex (PHIS), race (PHIS), weight (STS-CHS), the presence
of any noncardiac/genetic abnormality (STS-CHS), any preoperative risk
factor (as defined in the STS-CHS Database), any previous cardiothoracic
surgery (STS-CHS), STS-EACTS risk category for the primary procedure
performed (STS-CHS), the use of perioperative corticosteroids (PHIS), and
center average annual surgical volume of STS-EACTS classified opera-
tions (STS-CHS).12
Primary Exposure
The primary exposure variable was receipt of aprotinin, ACA, TXA, or
none of these medications on the day of the operation (PHIS).
Outcomes
The primary efficacy end point was a composite of in-hospital mortality
(PHIS) or bleeding requiring surgical intervention during the hospitaliza-
tion (STS-CHS). These outcomes were also examined individually. Other
outcomes evaluated included postoperative total and intensive care unit
lengths of stay (combination of STS-CHS and PHIS data). Postoperative
duration of mechanical ventilation in days was also collected (PHIS).
The primary safety end point was acute renal failure requiring temporary
or permanent dialysis (STS-CHS). Owing to reports in adults of possible
neurologic side effects of TXA, postoperative neurologic impairment (tran-
sient or permanent neurologic deficit or new-onset seizure; STS-CHS) was
also evaluated.13
Analysis
Variables were described using standard summary statistics. Unadjusted
outcomes were compared between groups using c2 andWilcoxon rank sum
tests. Multivariable analysis was also performed to evaluate outcomes as-
sociated with aprotinin, ACA, and TXA (as described below). All models
were adjusted for age, weight z-score, race, sex, any noncardiac/genetic ab-
normality or other STS-CHS preoperative risk factors, any previous cardio-
thoracic operation, STS-EACTS surgical risk category, and use ofrdiovascular Surgery c Volume 143, Number 3 551
TABLE 1. Patient and center characteristics in the overall cohort
Overall (n ¼ 22,258) Aprotinin (n ¼ 7329) TXA (n ¼ 1486) ACA (n ¼ 1667) No drug (n ¼ 11,766)
Age at operation, mo 7.6 (2.6-43.4) 8.1 (2.3-46.0) 6.5 (3.5-30.9) 7.9 (3.2-49.1) 7.6 (2.5-42.8)
Sex, male 12,431 (55.9%) 4121 (56.2%) 837 (56.3%) 935 (56.1%) 6538 (55.9%)
Race, white 15,729 (70.7%) 5272 (71.9%) 1064 (71.6%) 1250 (75.0%) 8143 (69.2%)
Weight, kg 6.9 (4.2-14.5) 7.1 (4.1-14.8) 6.4 (4.6-12.4) 7.0 (4.4-15.1) 6.9 (4.2-14.4)
Weight-for-age z-score 1.1 (2.1,0.2) 1.1 (2.1,0.2) 1.3 (2.3,0.3) 1.2 (2.1,0.2) 1.1 (2.2,0.2)
Noncardiac/genetic abnormality 6376 (28.7%) 1982 (27.0%) 496 (33.4%) 538 (32.3%) 3360 (28.5%)
Prematurity* 574 (14.0%) 215 (14.4%) 26 (12.6%) 37 (13.6%) 296 (13.9%)
Any STS preop risk factor 4955 (22.3%) 1599 (21.8%) 357 (24.0%) 402 (24.1%) 2597 (22.1%)
Previous CT surgery 7232 (32.5%) 2909 (39.7%) 554 (37.3%) 639 (38.3%) 3130 (26.6%)
STS-EACTS risk category
1 5465 (24.6%) 1496 (20.4%) 333 (22.4%) 367 (22.0%) 3269 (27.8%)
2 6354 (28.6%) 2177 (29.7%) 428 (28.8%) 499 (29.9%) 3250 (27.6%)
3 4112 (18.5%) 1364 (18.6%) 319 (21.5%) 352 (21.1%) 2077 (17.6%)
4 5063 (22.8%) 1786 (24.4%) 350 (23.6%) 355 (21.3%) 2572 (21.8%)
5 1264 (5.7%) 506 (6.9%) 56 (3.8%) 94 (5.6%) 608 (5.2%)
Periop corticosteroids 13,890 (62.4%) 5321 (72.6%) 1301 (87.6%) 1243 (74.6%) 6025 (51.2%)
Annual center volume, median
operations/y
376 (328-649) 370 (324-501) 649 (350-708) 376 (342-398) 393 (341-649)
Data are displayed as frequency and percent for dichotomous variables and median and interquartile range for continuous variables. TXA, Tranaxemic acid; ACA, aminocaproic
acid; STS, The Society of Thoracic Surgeons; CT, cadiothoracic; EACTS, European Association for Cardiothoracic Surgery. *Neonates only.
FIGURE 1. Antifibrinolytic use in children undergoing heart surgery.
TXA, Tranaxemic acid; ACA, aminocaproic acid.
Congenital Heart Disease Pasquali et al
C
H
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adjusted for prematurity. Our analytic approach was chosen specifically to
account for confounding by center, inasmuch as it was noted from initial
inspection of the data that choice of treatment appeared largely center de-
pendent, and historically it has been shown that both hospital care and out-
come can vary by center. For dichotomous outcome variables, conditional
logistic regression stratified by center was used to account for potential
confounding effect of center (this methodology also accounts for potential
differences in center volume). Odds ratios and 95% confidence intervals
are reported. For continuous outcome variables, linear regression with cen-
ter modeled as a main effect was used. Length of stay and duration of ven-
tilation were not normally distributed and were log transformed for
analysis. Regression coefficients from the linear regression models were
exponentiated, and the ratio of length of stay or duration of ventilation be-
tween groups with 95% confidence intervals (CIs) were reported. In cases
in which therewas a significant difference between groups, estimates of the
difference in actual days at the median value of length of stay or duration of
ventilation were also calculated. All analyses were performed in the overall
cohort and in 2 selected subgroups: (1) neonates and (2) thosewith a history
of cardiothoracic surgery undergoing redo sternotomy.
Outcomes were first evaluated in thosewho received aprotinin versus no
drug from 2004 to 2007 (the time period when aprotinin was commonly
used). Univariable and multivariable analyses were performed as outlined
above. Next, the second analysis focused on the years 2007 and 2008 when
there was a shift in use of aprotinin to use of ACA or TXA after aprotinin
was taken off the market. Outcomes associated with ACA and TXAwere
compared with aprotinin in univariable and multivariable analysis, again
as outlined earlier.
An instrumental variable analysis was then performed as an additional
method for comparative analysis of the 3 drugs, in an attempt to further
minimize potential confounding center effects. For this analysis, data
from 2008 were compared with those from 2007, restricting to centers
that switched primarily (>75% use) from aprotinin to ACA, from aprotinin
to TXA, and patients at these centers who received any antifibrinolytic
medication. All analyses were performed using SAS version 9.2 software
(SAS Institute, Inc, Cary, NC). Patients with missing data for a study end
point were excluded from analysis involving that end point. The P values
presented are without adjustment for multiple comparisons.552 The Journal of Thoracic and Cardiovascular SurgRESULTS
Study Population Characteristics
A total of 22,258 patients (25 centers) were included. Pa-
tient characteristics overall and for those who received each
antifibrinolytic medication are displayed in Table 1.
Change in medication use patterns is displayed in
Figure 1. During 2004 to 2007, 49% of patients overall re-
ceived an antifibrinolytic medication (42% aprotinin, 7%
ACA or TXA). In 2008, after aprotinin was taken off the
market, a similar proportion of patients overall received
an antifibrinolytic medication (43%), but only 5% received
aprotinin whereas 20% received ACA and 18% received
TXA. Overall, during the study period, 23 centers used
aprotinin, 20 centers used ACA, and 11 centers used
TXA. Of note, mortality in 2004 to 2007 versus 2008
was similar (3.6% vs 3.4%).ery c March 2012
TABLE 2. Unadjusted and adjusted postoperative outcomes associated with aprotinin versus no drug
Unadjusted results Adjusted results
Aprotinin No drug P value Aprotinin vs no drug P value
Overall n ¼ 7077 n ¼ 8644
In-hospital mortality 242 (3.4%) 317 (3.7%) .40 0.83 (0.68-1.04) .15
Bleeding requiring surgical invervention 122 (1.7%) 173 (2.0%) .20 0.76 (0.57-1.02) .07
Composite* 340 (4.8%) 455 (5.3%) .19 0.81 (0.68-0.97) .02
Dialysis 106 (1.5%) 102 (1.2%) .08 1.03 (0.74-1.45) .85
Neurologic deficit 113 (1.6%) 95 (1.1%) .007 1.18 (0.84-1.64) .34
Total LOS, d 8.7 (4.0-13.0) 7.9 (4.0-11.0) <.0001 1.02 (1.00-1.05) .11
ICU LOS, d 5.1 (2.0-8.0) 4.4 (2.0-7.0) <.0001 1.03 (0.99-1.06) .12
Duration of ventilation, d 3.4 (1.0-5.0) 3.0 (1.0-5.0) <.0001 1.04 (1.01-1.09)y .02
Redo sternotomy subgroup n ¼ 2819 n ¼ 2239
In-hospital mortality 64 (2.3%) 67 (3.0%) .11 0.57 (0.37-0.87) .009
Bleeding requiring surgical invervention 45 (1.6%) 61 (2.7%) .006 0.50 (0.30-0.85) .01
Composite* 102 (3.6%) 118 (5.3%) .004 0.56 (0.40-0.80) .001
Dialysis 29 (1.0%) 21 (0.9%) .74 0.96 (0.45-2.02) .91
Neurologic deficit 51 (1.8%) 27 (1.2%) .08 1.22 (0.68-2.20) .51
Total LOS, d 7.5 (4.0-10.0) 8.1 (5.0-11.0) .001 0.94 (0.90-0.98)z .006
ICU LOS, d 3.8 (2.0-6.0) 4.1 (2.0-6.0) .0002 0.90 (0.84-0.95)x .0004
Duration of ventilation, d 2.3 (1.0-3.0) 2.7 (1.0-4.0) .005 0.93 (0.87-1.00)k .04
Neonate subgroup n ¼ 1517 n ¼ 1700
In-hospital mortality 165 (10.9%) 207 (12.2%) .25 0.88 (0.66-1.17) .38
Bleeding requiring surgical invervention 49 (3.2%) 72 (4.2%) .14 0.91 (0.56-1.49) .71
Composite* 198 (13.1%) 256 (15.1%) .10 0.88 (0.67-1.14) .32
Dialysis 70 (4.6%) 70 (4.1%) .48 0.95 (0.61-1.48) .83
Neurologic deficit 49 (3.2%) 38 (2.2%) .08 1.23 (0.71-2.12) .46
Total LOS, d 19.0 (9.0-29.0) 19.2 (9.0-30.0) .60 0.99 (0.92-1.07) .85
ICU LOS, d 13.4 (6.0-20.0) 12.8 (6.0-20.0) .04 0.99 (0.91-1.07) .80
Duration of ventilation, d 7.3 (4.0-11.0) 7.1 (3.0-11.0) .02 1.00 (0.92-1.09) .93
LOS, Length of stay; ICU, intensive care unit. *Composite end point ¼ in-hospital mortality or bleeding requiring reoperation. Unadjusted results are displayed as frequency
(percent) for dichotomous variables and 10% trimmed means (interquartile range) for continuous variables. Adjusted results (from conditional logistic regression for dichoto-
mous variables and linear regression with center modeled as a main effect for continuous variables) are displayed as adjusted odds ratio (95% confidence intervals) for dichot-
omous variables and adjusted ratio of LOS or duration of ventilation (days) between groups for continuous variables. In those groups in which aprotinin was associated with
a significant difference in LOS or duration of ventilation, adjusted estimates of the difference in actual days (aprotinin vs no drug) at the median value of LOS or duration of
ventilation were also calculated: yOverall group, duration of ventilation (þ0.1 days); reoperation subgroup; ztotal LOS (0.5 days); xICU LOS (0.3 days); kduration of ventilation
(0.1 days).
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DSubsequent analyses were performed both in the overall
cohort of patients and in 2 subgroups: neonates
(n ¼ 4426) and those undergoing redo sternotomy
(n ¼ 7232). The most common procedures performed in
the neonate subgroup were Norwood operation (23%), arte-
rial switch operation (23%), coarctation/interrupted aortic
arch repair (13%), repair of total anomalous pulmonary ve-
nous connection (10%), and truncus arteriosus repair (4%).
The most common procedures performed in the reoperation
subgroup were Fontan operation (17%), bidirectional cav-
opulmonary anastomosis (14%), conduit operation
(10%), pulmonary valve replacement (4%), and subvalvu-
lar aortic stenosis repair (4%).Aprotinin Versus No Drug
We first evaluated outcomes associated with aprotinin
versus no drug in 2004 to 2007, the time period when apro-
tinin was most commonly used. Unadjusted and adjusted
outcomes are displayed in Table 2. In multivariableThe Journal of Thoracic and Caanalysis, aprotinin was associated with a significant reduc-
tion in the composite end point of in-hospital mortality/
bleeding requiring surgical intervention in the overall co-
hort. There was a statistically significant difference between
groups in duration of ventilation (0.1 days), likely not clin-
ically meaningful (Table 2). There were no other differ-
ences in outcome detected in the overall cohort including
no difference in renal failure requiring dialysis.
In the redo sternotomy subgroup, aprotininwas associated
with a significant reduction in mortality and bleeding requir-
ing surgical intervention, as well as reduced length of total
and intensive care unit length of stay.No differenceswere de-
tected in dialysis or neurologic complications (Table 2). In
the neonatal subgroup, aprotinin was not associated with
a significant difference in any outcome evaluated (Table 2).Aprotinin Versus TXA and ACA
Efficacy and safety outcomes were then compared in pa-
tients who received aprotinin, TXA, or ACA in 2007 andrdiovascular Surgery c Volume 143, Number 3 553
TABLE 3. Unadjusted and adjusted postoperative outcomes associated with TXA, ACA, and aprotinin
Unadjusted results Adjusted results
Aprotinin TXA ACA P value TXA vs aprotinin P value ACA vs aprotinin P value
Overall n ¼ 2247 n ¼ 1140 n ¼ 1478
In-hospital mortality 89 (4.0%) 23 (2.0%) 57 (3.9%) .009 0.39 (0.21-0.71) .002 1.30 (0.82-2.08) .27
Bleeding requiring surgical
invervention
52 (2.3%) 18 (1.6%) 38 (2.6%) .21 0.42 (0.22-0.77) .005 1.62 (0.91-2.88) .10
Composite* 132 (5.9%) 41 (3.6%) 79 (5.4%) .02 0.47 (0.30-0.74) .001 1.13 (0.77-1.67) .53
Dialysis 38 (1.7%) 9 (0.8%) 23 (1.6%) .10 0.23 (0.10-0.55) .0008 1.01 (0.51-1.98) .99
Neurologic deficit 56 (2.5%) 29 (2.5%) 25 (1.7%) .21 0.92 (0.51-1.65) .78 0.97 (0.54-1.74) .91
Total LOS, d 8.9 (4.0-14.0) 7.6 (4.0-11.0) 9.3 (5.0-14.0) <.0001 0.95 (0.89-1.01) .09 0.95 (0.90-1.01) .10
ICU LOS, d 5.2 (2.0-8.0) 4.3 (2.0-7.0) 5.3 (2.0-8.0) <.0001 0.92 (0.85-1.00)y .04 0.99 (0.92-1.06) .68
Duration of ventilation, d 3.3 (1.0-5.0) 2.7 (1.0-4.0) 3.3 (1.0-5.0) <.0001 0.80 (0.73-0.88)z <.0001 1.00 (0.92-1.08) .98
Redo sternotomy subgroup n ¼ 953 n ¼ 469 n ¼ 573
In-hospital mortality 18 (1.9%) 7 (1.5%) 19 (3.3%) .09 0.50 (0.16-1.57) .24 2.59 (1.04-6.45) .04
Bleeding requiring surgical
invervention
20 (2.1%) 6 (1.3%) 12 (2.1%) .51 0.40 (0.14-1.10) .08 1.42 (0.58-3.47) .44
Composite* 35 (3.7%) 13 (2.8%) 26 (4.5%) .32 0.63 (0.28-1.42) .26 1.31 (0.67-2.54) .43
Dialysis 8 (0.8%) 4 (0.9%) 4 (0.7%) .95 NA NA
Neurologic deficit 21 (2.2%) 18 (3.8%) 9 (1.6%) .05 1.57 (0.66-3.73) .31 1.12 (0.40-3.10) .83
Total LOS, d 7.5 (4.0-11.0) 7.1 (4.0-10.0) 8.2 (5.0-11.0) .0004 1.02 (0.94-1.12) .62 0.99 (0.91-1.08) .85
ICU LOS, d 3.9 (2.0-6.0) 3.3 (2.0-5.0) 4.3 (2.0-7.0) <.0001 1.02 (0.91-1.14) .76 1.03 (0.93-1.15) .55
Duration of ventilation, d 2.2 (1.0-3.0) 2.2 (1.0-3.0) 2.4 (1.0-4.0) .58 0.91 (0.80-1.04) .18 1.10 (0.97-1.25) .13
Neonate subgroup n ¼ 481 n ¼ 206 n ¼ 271
In-hospital mortality 67 (13.9%) 13 (6.3%) 32 (11.8%) .02 0.31 (0.14-0.69) .004 1.13 (0.59-2.18) .71
Bleeding requiring surgical
invervention
25 (5.2%) 6 (2.9%) 19 (7.0%) .14 0.30 (0.11-0.84) .02 2.81 (1.12-7.09) .03
Composite* 86 (17.9%) 19 (9.2%) 42 (15.5%) .02 0.30 (0.15-0.58) .0004 1.31 (0.73-2.34) .37
Dialysis 27 (5.6%) 4 (1.9%) 15 (5.5%) .09 0.12 (0.04-0.41) .0006 0.73 (0.30-1.77) .49
Neurologic deficit 29 (6.0%) 8 (3.9%) 10 (3.7%) .26 0.55 (0.20-1.51) .25 0.83 (0.30-2.27) .72
Total LOS, d 20.2 (9.0-32.0) 16.3 (9.0-23.0) 22.3 (11.0-36.0) .002 0.87 (0.75-1.01) .07 0.96 (0.83-1.11) .61
ICU LOS, d 14.3 (6.0-22.0) 12.2 (6.0-18.0) 14.6 (6.0-24.0) .18 0.82 (0.69-0.98)x .03 0.99 (0.84-1.17) .94
Duration of ventilation, d 7.0 (3.0-10.0) 5.5 (3.0-8.0) 8.3 (4.0-12.0) .0002 0.62 (0.52-0.74)k <.0001 0.92 (0.78-1.10) .37
TXA, Tranaxemic acid; ACA, aminocaproic acid; NA, not enough events to model. *Composite end point ¼ in-hospital mortality or bleeding requiring reoperation. Unadjusted
results are displayed as frequency (percent) for dichotomous variables, and 10% trimmed means (interquartile range) for continuous variables. Adjusted results (from conditional
logistic regression for dichotomous variables and linear regression with center modeled as a main effect for continuous variables) are displayed as adjusted odds ratio (95%
confidence intervals) for dichotomous variables and adjusted ratio of LOS or duration of ventilation (days) between groups for continuous variables. In those groups in which
aprotinin was associated with a significant difference in LOS or duration of ventilation, adjusted estimates of the difference in actual days at the median value of LOS or duration
of ventilation were also calculated: Overall group: yICU LOS, TXAvs aprotinin (0.3 days); zduration of ventilation, TXAvs aprotinin (0.4 days). Neonate subgroup: xICU LOS,
TXA vs aprotinin (1.8 days); kduration of ventilation, TXA vs aprotinin (2.3 days).
Congenital Heart Disease Pasquali et al
C
H
D2008 (the time period when use shifted from aprotinin to
TXA or ACA) in unadjusted and adjusted analysis
(Table 3). In multivariable analysis, there was generally
no difference detected in efficacy or safety outcomes com-
paring aprotinin with ACA overall or in the 2 subgroups,
with the exception of greater in-hospital mortality associ-
ated with ACA in the reoperation subgroup and greater
bleeding requiring surgical invervention in the neonatal
subgroup (Table 3). In contrast, TXAwas generally associ-
ated with improved outcomes in comparison with aproti-
nin. This included reduced in-hospital mortality, bleeding
requiring surgical invervention, intensive care unit length
of stay, and dialysis associated with TXA versus aprotinin
in the overall cohort (Table 3). In the neonatal subgroup,
similar differences were seen when comparing TXA with
aprotinin. In the redo sternotomy subgroup, no significant554 The Journal of Thoracic and Cardiovascular Surgdifferences between TXA and aprotinin were detected
(Table 3).
Instrumental Variable Analysis
An instrumental variable analysis was performed as a sec-
ond method for comparative analysis of the 3 drugs in an at-
tempt to further minimize potential confounding center
effects. Data from 2008 were compared with 2007, re-
stricted to centers that switched primarily (>75% use) to
ACA from aprotinin (n ¼ 7; 1553 patients) or switched pri-
marily to TXA from aprotinin (n¼ 3; 653 patients) and pa-
tients who received any antifibrinolytic medication at these
centers. Owing to the smaller number of patients, only the
composite end point could be modeled in the overall cohort
in multivariable analysis. Among centers that switched pri-
marily to TXA from aprotinin, there was not a significantery c March 2012
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quiring surgical intervention in 2008 (primarily TXA) ver-
sus 2007 (primarily aprotinin): adjusted odds ratio (OR),
0.53 (95% CI, 0.27-1.05; P ¼ .07). However, the point es-
timate was in the same direction as the primary analysis
noted earlier, favoring TXA. Among centers that switched
primarily to ACA from aprotinin, there was no difference
detected in in-hospital mortality or bleeding requiring sur-
gical intervention in 2008 (primarily ACA) versus 2007
(primarily aprotinin): adjusted OR, 0.85 (95% CI, 0.52-
1.41; P¼ .54). There were too few dialysis events to model
in multivariable analysis; however, in unadjusted analysis in
centers that switched primarily to TXA from aprotinin,
there was a reduction in renal failure requiring dialysis in
2008 (primarily TXA) versus 2007 (primary aprotinin):
0.7% versus 3.1%; P ¼ .03. In centers that switched pri-
marily to ACA from aprotinin, there was not a significant
difference detected in the proportion with renal failure re-
quiring dialysis in 2008 (primarily ACA) versus 2007 (pri-
marily aprotinin): 1.2% versus 2.7%; P ¼ .07. The overall
number of patients requiring dialysis in both cases was
small (9 and 32, respectively).
DISCUSSION
This multicenter contemporary analysis of antifibrino-
lytic medications in children undergoing heart surgery
suggests aprotinin is associated with reduced bleeding
requiring surgical intervention and mortality with no in-
crease in dialysis. Comparative analyses suggest similar ef-
ficacy of ACA and improved outcomes associated with
TXA.
Several previous studies of aprotinin in the pediatric pop-
ulation have suggested aprotinin is effective in reducing
bleeding after heart surgery, and a meta-analysis of 12 ran-
domized controlled trials (n ¼ 626) found that aprotinin re-
duced the proportion of children who received transfusions
during cardiac surgery by 33%.14 Our analysis of a contem-
porary cohort of more than 20,000 children suggests that
aprotinin is associated with reduced bleeding requiring re-
operation and mortality. These effects were most prominent
in the subgroup of patients undergoing redo sternotomy.
Previous analyses have suggested differential efficacy of
aprotinin, particularly in those at highest risk for bleeding.7
Costello and colleagues7 found that only those undergoing
reoperation had a significant decrease in transfusions asso-
ciated with aprotinin in an observational study of 112 chil-
dren undergoing heart surgery. Previous studies have also
reported a reduction in inflammatory markers in patients
who receive aprotinin, as well as a reduction in postopera-
tive myocardial dysfunction and inotropic support.15-17
These properties, along with the impact of aprotinin on
bleeding, may have contributed to the decreased length of
stay and duration of mechanical ventilation we observed
in the redo sternotomy subgroup.The Journal of Thoracic and CaHowever, many of the previous investigations have been
limited by important methodologic concerns including
small sample size, heterogeneous patient population, lack
of standardized transfusion protocols, and varying doses
of aprotinin used, and not all studies have demonstrated
a beneficial effect of aprotinin.14 In addition, in a previous
analysis of safety outcomes conducted by our group using
an administrative data source, we did not find a significant
impact of aprotinin onmortality overall or in those undergo-
ing reoperation.4 Analyses involving administrative data
must rely on ICD-9 codes from the hospital bill to identify
children undergoing heart surgery. In contrast, in the present
study we were able to use data from a clinical registry to
identify the study population. Using our linked data set,
which contains both the clinical registry data in the STS-
CHS Database and the ICD-9 codes from the administrative
database (PHIS) for each patient, we found that 10% of our
overall study cohort would not have been identified if we
had relied on ICD-9 codes alone, including 18% of patients
in the redo sternotomy cohort and 13% of patients in higher
STS-EACTS risk categories (categories 3-5) versus 6% of
patients in lower STS-EACTS risk categories (categories
1-2). It is possible that these differences may in part explain
differences in study results.
Regarding the safety of aprotinin, we did not find any dif-
ference in renal failure requiring dialysis in comparison
with no drug. Our data support results of previous single-
center observational analyses. Guzzetta and colleagues18
evaluated 200 neonates undergoing surgery for congenital
heart disease and found that aprotinin was not significantly
associated with postoperative creatinine levels or dialysis.
Backer and associates19 evaluated 1251 children and ado-
lescents undergoing surgery for congenital heart defects
and found that aprotinin was not associated with postoper-
ative renal failure or dialysis compared with historical con-
trols. Evaluation of safety was limited in the small
randomized trials of aprotinin in children, and in the recent
meta-analysis combining results from 12 trials, mortality
and renal failure could not be assessed.14
In comparative analyses, our observational data sug-
gested that, in general, ACA was associated with similar
or worse outcome than was aprotinin. There are few previ-
ous studies comparing outcomes in patients receiving dif-
ferent antifibrinolytic medications, and it is difficult to
draw conclusions owing to differences in study design, dos-
ing, outcomes, and small sample sizes. Chauhan and col-
leagues5 compared aprotinin with ACA in 300 children
undergoing heart surgery and found no difference in blood
loss, transfusion, and need for re-exploration.
In contrast, we found that TXA appeared to be associated
with better outcomes than aprotinin. These results differ
from a previous analysis of 100 children undergoing heart
surgery that found no difference in blood loss or transfusion
in those randomized to aprotinin versusTXA.6 This studyrdiovascular Surgery c Volume 143, Number 3 555
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different outcomes. The reasons for potentially greater effi-
cacy of TXA are unclear. There are limited pediatric phar-
macokinetic data available, and in our study wewere unable
to evaluate medication doses. It has been previously
reported that TXA may be a more potent inhibitor of fibri-
nolysis than ACA.20,21 In addition, TXA may have anti-
inflammatory properties.22
In regard to safety, we did not detect any difference com-
paring ACAwith aprotinin. TXA appeared to be associated
with a lower rate of dialysis than did aprotinin. However, the
overall number of events was small and it may be premature
to draw any conclusions from these data. There were also
few neurologic events in our study. Nonetheless, we did
not find any difference comparing ACA, TXA, and aproti-
nin. Previous case reports have suggested that TXA may
be associated with an increase in postoperative seizures in
adult patients undergoing cardiac surgery.13
Limitations
This study is subject to the limitations of all observa-
tional analyses. Our analytic strategy attempted to account
for known patient confounders; however, it is likely that
there are other variables not captured in these databases
that may affect both the receipt of antifibrinolytic medica-
tion and outcome. These may include differences in
bypass strategies. We also attempted to account for center
effects through our analytic approach using conditional
logistic regression and instrumental variable analysis.
However, these strategies may not account for all differ-
ences between centers, and our results may not be gener-
alizable to all centers performing surgery for congenital
heart defects.
Our study is also subject to the limitations of the data-
bases. Although our large sample size, multicenter data,
and combined data from both a clinical registry and ad-
ministrative database allowed evaluation of end points
such as mortality and other safety outcomes not able to
be assessed in previous single-center studies, we were
not able to evaluate other outcomes such as volume of
blood loss, transfusions, and more mild degrees of renal
impairment, inasmuch as these data are not collected in
the databases used. In addition, the data sources used for
this study also do not contain information on dosing or
indication for administration. Thus, we were not able to
compare specific doses of antifibrinolytic medications.
Rather, these data represent outcomes associated with
these medications in routine clinical practice across
multiple centers.
Finally, although this analysis represents the largest eval-
uation of these medications in the pediatric population, the
small sample size in certain subgroups, as well as the small
number of events, limited our analysis and power to detect
differences between groups in some cases. For example,556 The Journal of Thoracic and Cardiovascular Surgwe were unable to perform adjusted analyses of dialysis in
the instrumental variable analysis; thus these data are not
adjusted for patient risk andmust be interpretedwith caution.
In addition, our analysis involved multiple comparisons.
We chose not to adjust the P values or to specify a P value
cutoff for ‘‘significance’’ inasmuch as this methodology
can be somewhat subjective; however, we cannot rule out
the possibility that someof our findingsmaybe due to chance
alone.CONCLUSIONS
This large observational analysis of children undergoing
heart surgery suggests that aprotinin is associated with re-
duced bleeding requiring surgical intervention and mortal-
ity with no increase in dialysis in comparison with no
drug. Comparative analyses suggest similar efficacy of
ACA and improved outcomes associated with TXA. These
findings should be evaluated in an adequately powered clin-
ical trial.References
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